Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Sophie Pierce is determined to make the most of her life - however long she may have.

An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...

SION-2851 is under development for the treatment of cystic fibrosis. It is a small molecule administered orally. It is a first generation corrector. The drug candidate targets cystic fibrosis ...

LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...

DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...

Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.

Stockard has completed the interview portion of the competition and is now preparing for on-stage competition, which, for her, begins Wednesday.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...